The combination of ACEi and neprilysin inhibitors indeed effectively lowered angiotensin II level and blood pressure in hypertensive patients but facilitated a higher incidence of bradykinin accumulation-promoted angioedema [9], making the combination of ACEi/neprilysin inhibitor unfavorable. The gene discussed is MME; the disease is angioedema.